ProQR Therapeutics
PRQR
51 hedge funds and large institutions have $17.2M invested in ProQR Therapeutics in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.
1,088% more call options, than puts
Call options by funds: $95K | Put options by funds: $8K
12% less funds holding
Funds holding: 58 → 51 (-7)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
13.56% less ownership
Funds ownership: 44.61% → 31.05% (-14%)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
40% less capital invested
Capital invested by funds: $28.7M → $17.2M (-$11.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$826K |
| 2 |
MAM
Monaco Asset Management
Monaco
|
+$627K |
| 3 |
Renaissance Technologies
New York
|
+$242K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$235K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$6.35M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.79M |
| 3 |
Goldman Sachs
New York
|
-$459K |
| 4 |
Millennium Management
New York
|
-$443K |
| 5 |
CAC
Cowen and Company
New York
|
-$342K |
PRQR Hedge Fund Activity: Q2 2022 in Review
51 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2022, worth a combined $17.2M — down 40% from $28.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PRQR and 11 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was Prosight Management, adding an estimated $826K. The largest seller was RTW Investments, exiting entirely with an estimated $6.35M sold.
- 51 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2022, down from 58 in Q1 2022.
- Funds reported $17.2M of ProQR Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
- 11 funds opened new ProQR Therapeutics positions in Q2 2022 and 18 closed out, a net change of -7 holders.
- The largest ProQR Therapeutics buyer in Q2 2022 was Prosight Management, an estimated $826K added.
- The largest ProQR Therapeutics seller in Q2 2022 was RTW Investments, an estimated $6.35M sold.
Based on aggregated 13F filings for Q2 2022.